Atea Pharmaceuticals (AVIR) Net Cash Flow (2019 - 2026)

Atea Pharmaceuticals' Net Cash Flow history runs 8 years deep, the most recent figure standing at -$16.4 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 129.98% year-over-year to -$16.4 million in Q1 2026; TTM through Mar 2026 was -$40.1 million, a 3.47% increase from a year earlier, with the FY2025 full-year figure at $31.0 million, up 139.2% from the prior year.
• Net Cash Flow slipped to -$16.4 million in Q1 2026 per AVIR's latest filing, from $18.4 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $82.5 million in Q2 2024 and bottomed at -$508.1 million in Q3 2022.
• The 5-year median for Net Cash Flow is -$10.4 million (2025), against an average of -$40.3 million.
• Across the five-year window, Net Cash Flow tumbled 2271.42% in 2022 and surged 428.28% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at $11.9 million in 2022, then tumbled by 50.29% to $5.9 million in 2023, then tumbled by 668.76% to -$33.8 million in 2024, then surged by 154.4% to $18.4 million in 2025, then slumped by 189.26% to -$16.4 million in 2026.
• Per Business Quant, the three latest AVIR Net Cash Flow figures stand at -$16.4 million (Q1 2026), $18.4 million (Q4 2025), and -$10.4 million (Q3 2025).